Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Finished Goods (2024 - 2025)

Historic Finished Goods for Syndax Pharmaceuticals (SNDX) over the last 2 years, with Q3 2025 value amounting to $2.2 million.

  • Syndax Pharmaceuticals' Finished Goods changed N/A to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year change of. This contributed to the annual value of $36000.0 for FY2024, which is N/A changed from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Finished Goods stood at $2.2 million for Q3 2025.
  • Over the past 5 years, Syndax Pharmaceuticals' Finished Goods peaked at $2.3 million during Q1 2025, and registered a low of $36000.0 during Q4 2024.